Agora hosts high-dimensional human transcriptomic, proteomic, and metabolomic evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of over 900 nascent drug targets for AD that were nominated by AD researchers. The list of nominated targets was contributed by researchers from the National Institute on Aging's Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) consortium and Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) centers, as well as other research teams. Other evidence presented in Agora was either generated by AMP-AD and TREAT-AD research teams, or is aggregated from publicly available data sources.
Additional information about Agora is available in the Agora Resources documentation.
We encourage you to use the data and insights presented in Agora along with the following acknowledgement statement:
The results published here are in whole or in part based on data obtained from Agora, a platform initially developed by the NIA-funded AMP-AD consortium that shares evidence in support of AD target discovery. Agora is available at: doi:10.57718/agora-adknowledgeportalAgora is funded by the National Institute on Aging. It is developed and maintained by Sage Bionetworks. If you have questions, suggestions, or feedback about Agora, please contact us at: agora@sagebionetworks.org.